NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Forecast & News

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its earnings results on Wednesday, October, 23rd. The biopharmaceutical company reported $2.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.47 by $0.32. The biopharmaceutical company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.24 billion. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. Alexion Pharmaceuticals's revenue for the quarter was up 23.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.02 earnings per share. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Alexion Pharmaceuticals issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.95744 billion, compared to the consensus revenue estimate of $4.91 billion.

19 equities research analysts have issued 1-year target prices for Alexion Pharmaceuticals' stock. Their forecasts range from $125.00 to $186.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $154.39 in the next twelve months. This suggests a possible upside of 42.2% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.

Headlines about ALXN stock have been trending very positive on Friday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 3.9 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Alexion Pharmaceuticals.

Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Alibaba Group (BABA), Celgene (CELG), Micron Technology (MU), Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), AbbVie (ABBV), Broadcom (AVGO), Visa (V) and Biogen (BIIB).

Alexion Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Calamos Advisors LLC (0.31%), Candriam Luxembourg S.C.A. (0.26%), Empire Life Investments Inc. (0.11%), Peregrine Capital Management LLC (0.07%), Rhenman & Partners Asset Management AB (0.06%) and Vigilant Capital Management LLC (0.05%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Christopher J Coughlin, Daniel Bazarko, Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., Assenagon Asset Management S.A., State of Alaska Department of Revenue, DNB Asset Management AS, Meag Munich Ergo Kapitalanlagegesellschaft MBH and Vigilant Capital Management LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko and Indrani Lall Franchini. View Insider Buying and Selling for Alexion Pharmaceuticals.

ALXN stock was acquired by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Alpine Global Management LLC, Empire Life Investments Inc., RBA Wealth Management LLC, Cozad Asset Management Inc., Zurcher Kantonalbank Zurich Cantonalbank , Webster Bank N. A. and BKD Wealth Advisors LLC. View Insider Buying and Selling for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $108.55.

Alexion Pharmaceuticals has a market capitalization of $24.02 billion and generates $4.13 billion in revenue each year. The biopharmaceutical company earns $77.60 million in net income (profit) each year or $7.09 on an earnings per share basis. Alexion Pharmaceuticals employs 2,656 workers across the globe.View Additional Information About Alexion Pharmaceuticals.

The official website for Alexion Pharmaceuticals is http://www.alexion.com/.

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]